Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.

Future Microbiol · 2021 · PMC8579950 · PMID 34755538

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Another study showed a trend in fewer hospitalizations in the sofosbuvir/daclatasvir arm, but without any significant difference [ 71 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.